AtriCure, Inc. - Common Stock (ATRC)

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.

Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but it also means giving up some upside when risk appetite shifts toward early-stage biotech companies.

This medical device innovator for cardiac surgery reported a notable insider sale amid a year of negative total returns.

AtriCure (ATRC) Q4 2025 Earnings Call Transcript

This cardiac device maker focused on atrial fibrillation saw a notable insider sale following a year of flat share performance.

AtriCure (ATRC) Q3 2025 Earnings Call Transcript

AtriCure's Q3 2025 earnings beat expectations with a narrowed loss and strong revenue growth. The medical device firm also raised its full-year financial outlook.

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.